Homecare

We helped the Cardiology branch of one of our pharmaceutical industrial clients to understand if a start-up developing a home medical device, which measures a cardiological parameter of interest, could be an appropriate partner for a strategic investment; and if the medical device of this start-up could be profitable as a standalone product within a 3-5 year timeframe.

To do this, our team first carried out an analysis of the start-up’s commercial prospects via a benchmark of similar companies’ activities, an in-depth study of the competition, and an estimate of the market potential in several geographies. We then carried out a strategic audit of the assets of the start-up.

Ultimately, our analysis of these information enabled us to recommend the inclusion of the device in question in our client’s portfolio rather than marketing it as a stand-alone product.

We supported a medical device player and a medical nutrition player in assessing the opportunity to develop a joint enteral nutrition offer on the German home care market.

The objectives of our mission were to understand the drivers of the enteral nutrition market and to identify the main challenges faced by home care providers in Germany, as well as their enteral nutrition needs and expectations.

Alcimed thus analyzed the home enteral nutrition market in Germany through an in-depth literature review and interviews with different profiles, including home care providers, dietitians, hospital discharge teams, neonatologists and pharmacists.

We accompanied one of our clients in understanding the homecare market in Switzerland with the objective of validating the development of a new medical solution.

To do so, our team deciphered the landscape of home care in Switzerland by identifying and analyzing the key players and in particular: their offers, their training programs, their IT skills, as well as their organization. We then cross-analyzed the strengths and weaknesses of each player before recommending to our client a pilot concept to be deployed in the Swiss market.

We supported our client in defining new product and service offerings that create value for home care providers in France.

Alcimed first analyzed the needs and expectations of home healthcare providers in terms of products and services in order to define a series of potential concepts to be developed. We then selected a list of the 20 most relevant concepts for our client before analyzing their relevance in more detail via an in-depth field investigation. Ultimately, we recommended to our client the 3 most value-creating offers for home care providers and the most adapted to his context.

Alcimed worked with a large pharmaceutical player to understand the possibilities of primary cancer treatment at home in terms of adequate molecule, administration and country-specific requirements.

Across France, Germany and the USA, we mapped existing molecules administered at home as well as those in development. We then evaluated the organization of at-home SC/IV treatments and the drivers and barriers fostering or limiting the development of at-home treatments in each country in scope. Finally we challenged these findings with interviews with top KOLs.

The mapping exercise and following analysis gave the client a clear vision of the development of home-administrable molecules in oncology at a global level, and of the current and potential future practices in France, Germany and the USA. This vision will help him to structure their R&D strategies and engagement with relevant stakeholders.

Alcimed supported a top pharmaceutical client in identifying changes and innovations made in the patient pathway for a rare pulmonary disease during COVID-19.

Across five countries, we investigated solutions implemented as a reaction to the COVID-19 pandemic including remote homecare offers as well as administrative processes. Via interviews with pulmonologists, we identified changes in the patient pathway for the disease as well as evaluated the reactions of HCPs. We identified both large and small changes in the patient pathway and captured the current environment in which hospitals operate to provide care to patients with rare pulmonary disease.

In the end, our work enabled to capture the perception of relevant stakeholders on the advantages and disadvantages of remote disease monitoring and telehealth offers.